A groundbreaking international research project is investigating a simple finger-prick blood test that could revolutionize Alzheimer’s disease diagnosis. The trial focuses on three proteins in the blood associated with Alzheimer’s, and scientists are comparing the new test with the current ‘gold standard’ of brain scans. With 1,000 volunteers worldwide, the study could pave the way for an easier, cost-effective diagnostic tool for Alzheimer’s.
Currently, diagnosing Alzheimer’s involves expensive, complex procedures like brain scans, lumbar punctures, or spinal taps. If successful, the finger-prick blood test would offer a more accessible and less invasive alternative. The test uses a plasma separation card to enhance the speed and accuracy of Alzheimer’s diagnosis by analyzing blood and digital biomarkers. A simpler, quicker test could allow for earlier intervention, which is crucial in managing the disease’s progression.
The research is part of the Global Alzheimer’s Platform Foundation’s Bio-Hermes-002 study, backed by the medical research organization LifeArc. As of now, 883 volunteers from the UK, USA, and Canada have been enrolled, with more than 360 completing the test. Participants include individuals without symptoms, those with mild cognitive impairment, and some with mild to moderate Alzheimer’s disease.
Dr. Giovanna Lalli, Director of Strategy and Operations at LifeArc, commented on the progress: “Over the last five years, there has been substantial progress in identifying blood-based biomarkers to detect Alzheimer’s before symptoms appear. Developing cheaper, scalable, and accessible tests is essential in fighting this devastating disease.”
John Dwyer, President of the Global Alzheimer’s Platform, expressed excitement about the potential of the blood test, noting that it could significantly change the way Alzheimer’s is diagnosed. However, additional work will be required to bring the test to market after the trial concludes.
Prof. Henrik Zetterberg, lead of the Biomarker Factory at the UK Dementia Research Institute, emphasized the importance of comparing the results of this new test with current diagnostic techniques. He noted, “If successful, a minimally invasive and cost-effective test could revolutionize Alzheimer’s diagnostics and set the stage for improved diagnosis of all neurodegenerative conditions.”
The trial is expected to be completed by 2028. Currently, there are approximately 944,000 people living with dementia in the UK, with an estimated seven million in the US. Alzheimer’s disease affects around six in 10 people with dementia, and early signs typically include memory problems, reasoning difficulties, and language challenges.
This innovative blood test could help accelerate the development of new treatments and provide greater access to early-stage interventions, making it a significant milestone in the fight against Alzheimer’s.
